Metformin and the gastrointestinal tract.

Diabetologia
Laura J McCreightEwan R Pearson

Abstract

Metformin is an effective agent with a good safety profile that is widely used as a first-line treatment for type 2 diabetes, yet its mechanisms of action and variability in terms of efficacy and side effects remain poorly understood. Although the liver is recognised as a major site of metformin pharmacodynamics, recent evidence also implicates the gut as an important site of action. Metformin has a number of actions within the gut. It increases intestinal glucose uptake and lactate production, increases GLP-1 concentrations and the bile acid pool within the intestine, and alters the microbiome. A novel delayed-release preparation of metformin has recently been shown to improve glycaemic control to a similar extent to immediate-release metformin, but with less systemic exposure. We believe that metformin response and tolerance is intrinsically linked with the gut. This review examines the passage of metformin through the gut, and how this can affect the efficacy of metformin treatment in the individual, and contribute to the side effects associated with metformin intolerance.

References

Apr 1, 1992·British Journal of Pharmacology·C J BaileyC Day
Sep 1, 1989·Diabetes Care·C J Bailey, C Day
May 1, 1987·Diabetes·R A JacksonA B Kurtz
Aug 1, 1981·British Journal of Clinical Pharmacology·G T TuckerH F Woods
Jun 1, 1994·British Journal of Pharmacology·C J BaileyT Page
Jan 1, 1994·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·C Wilcock, C J Bailey
May 1, 1996·Clinical Pharmacokinetics·A J Scheen
Jan 24, 1998·The New England Journal of Medicine·R I MisbinG A Fleming
Aug 14, 1998·Diabetic Medicine : a Journal of the British Diabetic Association·J H ScarpelloH C Howlett
Jan 29, 2000·Naunyn-Schmiedeberg's Archives of Pharmacology·L X CubedduH Schwörer
Sep 30, 2000·British Journal of Clinical Pharmacology·P H MaratheI R Wilding
Mar 9, 2002·Biochemical and Biophysical Research Communications·Simon A HinkeHans-Ulrich Demuth
Jul 19, 2002·Drug Metabolism and Disposition : the Biological Fate of Chemicals·David StepenskyAmnon Hoffman
Sep 5, 2002·Nature Reviews. Cancer·Sanjiv Sam Gambhir
Oct 31, 2002·Diabetes, Obesity & Metabolism·D CarterC Bailey
Nov 7, 2002·Biochemical and Biophysical Research Communications·Nobuyuki YasudaIsao Tanaka
Mar 13, 2003·Diabetes, Obesity & Metabolism·D CarterC J Bailey
Jul 29, 2003·Pflügers Archiv : European journal of physiology·Hermann Koepsell, Hitoshi Endou
Sep 28, 2004·The Journal of Biological Chemistry·Karen EngelJoanne Wang
Apr 22, 2005·Diabetic Medicine : a Journal of the British Diabetic Association·J R LindsayP M Bell
Aug 16, 2005·Molecular Pharmacology·Karen Engel, Joanne Wang
Nov 3, 2005·Biochemical Pharmacology·Johanna MüllerMatthias Brandsch
Jun 30, 2007·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Mingyan ZhouJoanne Wang
Sep 6, 2007·European Journal of Nuclear Medicine and Molecular Imaging·Eric GontierJean-Louis Alberini
May 7, 2008·Drug Metabolism and Disposition : the Biological Fate of Chemicals·William R ProctorDhiren R Thakker
Jun 6, 2008·Diabetologia·C J BaileyJ H B Scarpello
Jun 23, 2009·Diabetic Medicine : a Journal of the British Diabetic Association·J CuthbertsonP M Bell
Sep 3, 2009·Cell Metabolism·Charles ThomasKristina Schoonjans
Jan 19, 2011·Clinical Pharmacokinetics·Garry G GrahamKenneth M Williams

❮ Previous
Next ❯

Citations

Mar 29, 2016·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·H J BurtK Rowland-Yeo
Apr 12, 2016·Nature Reviews. Endocrinology·Kaixin ZhouEwan R Pearson
May 8, 2016·Atencion primaria·Consuelo Laudo Pardos, Víctor Puigdevall Gallego
Jan 24, 2016·Diabetic Medicine : a Journal of the British Diabetic Association·E R Pearson
Sep 7, 2016·Diabetologia·Patrick Schrauwen, Wouter D van Marken Lichtenbelt
Oct 1, 2016·Diabetes, Obesity & Metabolism·Tahseen A ChowdhuryM Magdi Yaqoob
Oct 21, 2016·Diabetes, Obesity & Metabolism·Tongzhi WuChristopher K Rayner
Dec 20, 2016·Journal of Internal Medicine·L Fändriks
Jan 6, 2017·Clinical and Translational Gastroenterology·Sayali A PendharkarMaxim S Petrov
Nov 20, 2016·Clinical Pharmacology and Therapeutics·T DujicE R Pearson
Feb 18, 2017·Nutrients·Fedra Luciano-MateoJorge Joven
Dec 18, 2016·Diabetes, Obesity & Metabolism·Fabrice Bonnet, André Scheen
Feb 23, 2017·Archives of Endocrinology and Metabolism·Miriam Méndez-Del VillarManuel González-Ortiz
Apr 6, 2017·International Journal of Molecular Sciences·Jorge HidalgoRafael A Burgos
May 6, 2017·Diabetes, Obesity & Metabolism·Thomas A BicsakMark Fineman
Jan 25, 2017·Current Diabetes Reports·Yoshihito Fujita, Nobuya Inagaki
Apr 19, 2017·Diabetes, Obesity & Metabolism·Jean-Daniel LalauNicolas Wiernsperger
Feb 20, 2018·Diabetes, Obesity & Metabolism·Laura J McCreightEwan R Pearson
Dec 23, 2017·BioMed Research International·Mona P NasrallahMarwan M Refaat
Nov 22, 2017·Journal of Biomedical Science·Shaghayegh NorouziStephen Myers
Nov 24, 2017·Npj Aging and Mechanisms of Disease·Irene AlfarasRafael de Cabo
Sep 8, 2017·Expert Review of Clinical Pharmacology·André J Scheen
Nov 30, 2016·The Cochrane Database of Systematic Reviews·Emma MeadLouisa J Ells
Apr 11, 2018·Current Opinion in Clinical Nutrition and Metabolic Care·Julie RodriguezNathalie M Delzenne
May 13, 2018·Diabetes, Obesity & Metabolism·Peter BreiningNiels Jessen
Jun 5, 2018·Diabetes, Obesity & Metabolism·Peter ArnerMikael Rydén
Aug 3, 2018·Expert Opinion on Drug Safety·André J Scheen
Dec 26, 2018·International Journal of Molecular Sciences·Raphaëlle CorremansAnja Verhulst
Jan 17, 2019·PloS One·Dorota LatekJudyta Cielecka-Piontek
Apr 26, 2019·Diabetes/metabolism Research and Reviews·Alexey V ZilovImran Paruk

❮ Previous
Next ❯

Methods Mentioned

BETA
imaging technique
biopsies
biopsy

Software Mentioned

Glucophage
GoDARTS

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.